CanaQuest Medical Corp. announced its US launch of all-natural Mentanine® (cannabidiol "CBD" + IP, Omega-3s, DHA, EPA formula) in California for distribution across the United States and international export. Proprietary Formulation - IP protected, International Patents filed, and Pre-clinical Trial results - published in peer-reviewed European Journal of Neuroscience (Oct.

2020). New Pathway Discovery - molecules bond and synergistically attach to Peroxisome proliferator-activated receptors (PPARs) allowing the formula to cross the blood-brain barrier (BBB) to target the central nervous system (the brain) with amplified effects and efficacy. CBD by itself did not do this in the pre-clinical trials.

Mentanine® was developed by Dr. Steven Laviolette, a neuroscientist and scientific veteran with decades of research experience in the field of mental health and cannabinoids. Dr. Laviolette and his dedicated team of 13 scientists at Western University focus on neuropsychiatric disorders like anxiety, depression, post-traumatic stress disorder (PTSD), and addiction.